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AbstrACt
Objectives Men diagnosed with non-metastatic 
prostate cancer require standardised and robust long-
term prognostic information to help them decide on 
management. Most currently-used tools use short-term 
and surrogate outcomes. We explored the evidence base 
in the literature on available pre-treatment, prognostic 
models built around long-term survival and assess the 
accuracy, generalisability and clinical availability of these 
models.
Design Systematic literature review, pre-specified and 
registered on PROSPERO (CRD42018086394).
Data sources MEDLINE, Embase and The Cochrane 
Library were searched from January 2000 through 
February 2018, using previously-tested search terms.
Eligibility criteria Inclusion required a multivariable 
model prognostic model for non-metastatic prostate 
cancer, using long-term survival data (defined as ≥5 
years), which was not treatment-specific and usable at the 
point of diagnosis.
Data extraction and synthesis Title, abstract and full-
text screening were sequentially performed by three 
reviewers. Data extraction was performed for items in 
the CHecklist for critical Appraisal and data extraction 
for systematic Reviews of prediction Modelling Studies 
checklist. Individual studies were assessed using the new 
Prediction model Risk Of Bias ASsessment Tool.
results Database searches yielded 6581 studies after 
deduplication. Twelve studies were included in the final 
review. Nine were model development studies using data 
from over 231 888 men. However, only six of the nine 
studies included any conservatively managed cases and 
only three of the nine included treatment as a predictor 
variable. Every included study had at least one parameter 
for which there was high risk of bias, with failure to 
report accuracy, and inadequate reporting of missing data 
common failings. Three external validation studies were 
included, reporting two available models: The University 
of California San Francisco (UCSF) Cancer of the Prostate 
Risk Assessment score and the Cambridge Prognostic 
Groups. Neither included treatment effect, and both had 
potential flaws in design, but represent the most robust 
and usable prognostic models currently available.
Conclusion Few long-term prognostic models exist to 
inform decision-making at diagnosis of non-metastatic 
prostate cancer. Improved models are required to inform 
management and avoid undertreatment and overtreatment 
of non-metastatic prostate cancer.
IntrODuCtIOn
Prostate cancer (PCa) is the most common 
male cancer and its incidence is increasing, 
with 1.3 million estimated new cases globally 
in 2018.1 2 The vast majority of new presenta-
tions in the UK (>80%) are with localised or 
locally advanced disease representing a signif-
icant healthcare and economic burden.3 
Treatment decisions, in this growing group 
of men, are notoriously complex with the risk 
of progression and psychological impact of a 
cancer diagnosis balanced against significant 
potential morbidity associated with treatment. 
These latter problems can be very significant 
with rates of erectile dysfunction as high as 
79% and 66% 3 years after prostatectomy and 
radiotherapy, respectively, and incontinence 
rates of 20% and 3%, respectively4. As a result 
of this, the uptake of conservative manage-
ment is increasing with rising confidence in 
using active surveillance.5 6 The predominant 
decision dilemma is therefore at the point of 
diagnosis when men are considering treat-
ment options and indeed whether treatment 
is needed, particularly given the fact that 
many men may have indolent disease and are 
strengths and limitations of this study
 ► Comprehensive and focused search strategy on 
prognostic models built around survival outcomes 
rather than shorter-term surrogates.
 ► Contemporary clinical review of model accuracy and 
usability, to inform clinical practice.
 ► Thorough bias assessments of individual studies, 
utilising the newly developed PROBAST tool.
 ► Unable to assess bias across studies, publication 
bias and selective reporting.
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more likely to die of non prostate cancer related causes. 
This point is highlighted in the work of Lloyd et al who 
showed that the lifetime incidence of being diagnosed 
with the disease is 13.4% but the risk of dying from the 
disease is only 4.3%.7 
Most national guidelines currently risk-stratify men 
according to modified versions of the three-stratum 
D’Amico classification system, first proposed in 19988. 
This used biochemical recurrence as the primary 
outcome from a cohort of men all managed by radical 
treatment. However, biochemical recurrence is known to 
be a poor surrogate for survival and many men will no 
longer undergo radical treatment.5 6 9 The value of this 
system is therefore questionable, especially given its use 
has moved from predicting radical therapy outcomes 
to counselling men at diagnosis about whether to have 
surveillance or treatment. Alternative risk models have 
been proposed to delineate smaller groups using stan-
dard variables (prostate-specific antigen (PSA), Gleason 
score, T-stage) or which integrate additional parame-
ters, such as biopsy characteristics.10–12 However, many 
are built around single-centre data, using PSA-screened 
and heavily radically-treated populations, making them 
less applicable to the fundamental decision dilemma of 
whether treatment is needed in the first place.
Prognostic models, according to the American Joint 
Committee on Cancer (AJCC), should use survival itself 
as an endpoint, which is less equivocal and more robust.13 
Using survival is especially important in prostate cancer 
given the slow natural history of the disease. In other 
tumour-types, high quality prognostic models using long-
term survival are already integrated into routine practice 
and endorsed by the AJCC.14 However, no prognostic 
model for PCa has yet been endorsed, nor to our knowl-
edge, is any such model widely-used in routine clinical 
practice. Models integrating the impact of radical treat-
ment compared with conservative management would be 
particularly powerful.
Our objective in this study was therefore to perform 
a rigorous systematic search of the literature to identify 
available prognostic models built specifically around 
long-term patient survival, available for use at the point of 
a new diagnosis of primary non-metastatic PCa. Our aims 
were to establish (i) what models were available (ii) their 
accuracy in terms of discrimination and calibration and 
(iii) their generalisability, external validation and clinical 
utility.
MEthODs
The study protocol followed the recommendations of 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines.15 The review aim, 
search strategy and study inclusion and exclusion criteria 
were framed using the CHecklist for critical Appraisal 
and data extraction for systematic Reviews of prediction 
Modelling Studies (CHARMS).16 The search strategy 
was informed by previous similar studies, including 
publications which tested and recommended search 
terms for risk-prediction models.17 18 The full systematic 
review protocol was pre-specified and registered through 
PROSPERO, reference CRD42018086394 (https://www. 
crd. york. ac. uk/ prospero/) and is available in the online 
supplementary files.
In summary, this was a review of studies reporting multi-
variable long-term survival models for use at the point of 
diagnosis for men newly diagnosed with non-metastatic 
PCa. Long-term survival, was defined as ≥5 years following 
diagnosis. We focused on publications subsequent to 
January 2000 to increase relevance to modern practice. 
For inclusion, studies needed to include men under-
going more than one treatment type and models should 
be multivariable. Models for cancer-specific or all-cause 
survival outcomes were potentially eligible, and any even-
tual model types were allowable. Both model development 
and model validation studies were eligible. Single-param-
eter or single-treatment studies were excluded. Compre-
hensive study inclusion and exclusion criteria are shown 
in box 2.
Information sources
Studies were identified by searching MEDLINE, Embase 
and Cochrane Library from 1 January 2000 to 28 
February 2018. Detailed search strategies for each data-
base are available in the online supplementary data. 
Highly relevant but excluded articles were recorded, 
collated and the references analysed for additional 
studies.
box 1 Eligibility criteria for study inclusion and exclusion
study inclusion criteria
All of the following inclusion criteria must be met:
 ► Studies reporting models based on men with non-metastatic pros-
tate cancer.
 ► Studies evaluating ‘long-term’ (≥5 years) cancer-specific or overall 
survival outcomes.
 ► Studies reporting models in screened or non-screened populations.
 ► Studies including men undergoing more than one treatment option.
 ► Models available for use at the point of diagnosis – that is, 
pre-treatment.
 ► The model includes more than one parameter, that is, multivariable.
study exclusion criteria
Any of the following is a reason to exclude a study:
 ► Any article that is not an original study (eg, reviews, commentary, 
editorials, corrigendums, letters).
 ► Conference proceeding or abstract from poster/oral communication 
only.
 ► Study where data cannot be derived to contribute to a primary or 
secondary outcome of this systematic review.
 ► Studies pertaining only to men with advanced/metastatic disease.
 ► Studies pertaining exclusively to men after an active treatment op-
tion for example, after radical prostatectomy.
 ► Studies of single biomarkers or single parameters only.
 ► Studies including men exclusively undergoing a single treatment 
type.
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Data management
Search results were exported into Covidence software, 
an online screening platform endorsed by Cochrane ( 
covidence. org). Title and abstract screening and full-text 
screening were sequentially performed by a team of three 
reviewers. Prior to screening, a pilot screening process 
was conducted for calibration of screening between 
reviewers. Reviewers were not blinded to study authors, 
institution, publication journal or year of publication.
Data items
The full list of data items extracted from each included 
study is recorded in the protocol. These were informed by 
the CHARMS checklist16 and included: (1) Study design, 
(2) Characteristics of study participants, (3) Outcomes, 
(4) Candidate predictors, (5) Sample size, (6) Missing 
data, (7) Statistical methods, (8) Model performance 
and evaluation and (9) Usability. Model performance, 
assessed by discrimination was the principal summary 
measure.
bias assessment
To assess the validity of eligible studies, individual studies 
were assessed for bias using the new Prediction model Risk 
Of Bias ASsessment Tool (PROBAST).19 The PROBAST 
tool assesses both risk of bias and applicability of both 
model development studies and validation studies.20
Patient and public involvement
There was no formalised patient and public involvement 
in the design or conduct of this review. Preliminary results 
were presented to a departmental patient and public 
involvement group, and their comments used to inform 
the write-up of the review.
rEsults
study selection
The search of Cochrane, MEDLINE and Embase yielded 
6581 studies after deduplication. Sixteen additional 
studies were identified by reviewing the references of 
excluded but relevant studies. A total of 12 studies were 
eligible for inclusion in the final review.21–32 Two of these 
had not been summarised in previous reviews.26 27 The 
PRISMA flow diagram is shown in figure 1, including 
the reasons for exclusion at full-text screening. Only 
one reason for exclusion was assigned to each study, 
when multiple reasons may have been present. Nine of 
the final 12 included studies were model development 
studies, three were model validation studies. Two of these 
external validations were of models already included as 
model development studies.30 31 One study related to an 
external validation of the Cancer of the Prostate Risk 
Assessment (CAPRA) score against mortality.32 The orig-
inal CAPRA model development study however did not 
meet the eligibility criteria as it was developed against 
recurrence rather than long-term survival.11
study characteristics
Characteristics of the included studies’ participants and 
settings are summarised in table 1. The model develop-
ment studies used data from over 231 888 men. However, 
two studies used analytical cohorts from the same registry 
(Surveillance, Epidemiology and End Results (SEER)).23 29 
Two studies used data from single US centres, two used 
data from groups of four hospitals, and five were from 
regional or national multicentre registries. Eligibility 
criteria of patients into studies varied significantly, with 
some models using very specific or selected sub-cohorts 
only. For example Nguyen et al included only consenting 
men, undergoing radiotherapy (RT) or radical pros-
tatectomy (RP), with at least one intermediate or high-
risk feature but ≤T3b disease.22 The treatment cohorts 
included, and whether treatment effect was a parameter 
in the final model was highly variable. Only six of the 
nine models included any men who had been managed 
conservatively (including ‘watchful waiting’ or ‘conser-
vative management’); none of the models described or 
defined a specific ‘active surveillance’ cohort.21 23 25 27–29 
Only three of the nine models included treatment as a 
predictor variable - none of which were externally vali-
dated.24 25 28 Median follow-up was relatively short within 
all model development cohorts, with the longest reported 
follow-up being 7.6 years26.
results of individual studies
The final results of individual studies are summarised 
in table 2. The primary outcome was cancer-specific 
mortality only in one study,27 and was overall-survival only 
in another study.25 The remainder reported measures 
of both. The study designs, model-types and perfor-
mance metrics varied markedly. We therefore focused 
on describing the studies, results, applicability and avail-
ability. Significant heterogeneity in the question being 
asked and statistical methods of validation between 
Figure 1 PRISMA flow diagram depicting the flow 
of information through the different phases of the 
review. PRISMA, Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses. 
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studies meant that attempts to meta-analyse data would 
not be appropriate. Modelling techniques varied, with 
the majority of studies using a proportional hazards 
model (Cox or Fine and Grey) although none reported 
assessing whether the proportional hazards assumption 
was valid. Included studies did not report any flexible 
parametric approaches to deal with continuous variables, 
and the majority used group categorisations of these 
variables. Reporting of model accuracy was inconsistent. 
Considering area under the curve and c-indices synony-
mously, six of the nine studies reported some measure of 
discrimination with values ranging from 0.63 to 0.90 for 
PCa survival outcomes, although this higher figure was 
derived within a small elderly sub-cohort23 28 and 0.58 to 
0.73 for overall outcomes.23 25 Only four of the nine studies 
reported assessing calibration in some capacity.23 25–27 
Relative performance within particular sub-populations 
were not generally reported.
Validation
Seven of the nine model development studies reported 
internal validation. Two reported using bootstrapping, 
and one used a separate 40% random sample of the orig-
inal dataset for internal validation.21 26 27 An additional 
three external validation papers were included (table 3). 
Of note, each of these included the author of the original 
model within their author list, suggesting these are not 
completely independent validations. These three models 
each used large numbers of subjects over comparable 
timeframes to their model development study. Discrimina-
tion of the Cambridge Prognostic Groups, SEER Cancer 
Survival Calculator and CAPRA scores were comparable 
for prostate cancer specific mortality (PCSM) at 0.81, 0.81 
and 0.80, respectively, over 5 years30-32 (table 4). Discrimi-
nation was poorer for overall mortality at 0.71 in the latter 
study. These external validation papers performed quite 
well on individual bias assessment (table 5). In the CAPRA 
validation paper estimates were reported to be ‘adjusted’ 
for age and treatment type, such that it is unclear whether 
the reported accuracy reflects that of the usable model.32
risk of bias
Risk of bias within studies is summarised in both table 5 
and figure 2. Frequent concerns were observed with 
respect to participant selection and inclusion, particularly 
with respect to reporting or allowing for missing data. 
The outcome of death was well-defined and unambig-
uous in the majority of studies. Every included study had 
at least one parameter for which there was high concern 
of bias – leading to a high overall judgement of bias in 
the PROBAST tool. Concerns about applicability to the 
review question were present in more than half of the 
studies.
usability
All of the included studies reported models that were 
nomograms, look-up tables or grouping stratifications. 
Seven of the nine studies were clinically usable through 
the publication itself. One was also available in a dedi-
cated website.31 The SEER Cancer Survival Calculator was 
never launched online, and the publication itself does not 
provide sufficient detail to use the model.23 The model by 
Margel et al was available but not usable as it included year 
of entry as a predictor variable, making the model usable 
only on retrospective series rather than in future indi-
vidual cases. Indeed, this model was developed to answer 
the question of whether pathological information adds to 




Treatment decisions at the point of diagnosis of non-met-
astatic PCa should be informed by the likely prognosis 
of the disease. Despite finding a number of published 
prognostic models, there remains a lack of well-vali-
dated, unbiased, generalisable models for use at diag-
nosis. In particular, there was a lack of external validation 
and dearth of models that compare outcomes between 
conservative management and radical treatment.
Prior evidence
A number of previous reviews have assessed ‘prediction’ 
or ‘risk’ models in their broadest sense.33–35 Shariat et al 
have previously published a thorough catalogue of avail-
able predictive models in PCa – predicting everything 
from detecting PCa in the initial biopsy setting to survival. 
Other reviews have focused exclusively on outcomes 
following radical prostatectomy or radiotherapy.36 37 
Lughezzani et al in 2010 for example summarised models 
predicting Gleason score upgrading, pathological stage, 
life expectancy, perioperative mortality, postopera-
tive biochemical recurrence or functional outcomes in 
addition to PCSM after prostatectomy.36 The paucity of 
models using mortality as an outcome was particularly 
noted and the study concluded that no tools were capable 
of quantifying the benefit of RP relative to other treat-
ment modalities.36 In 2009, a separate review by Shariat 
et al summarised available models into eight groups. One 
of these groups was of models predicting survival. This 
group included only four models, all of which related 
to advanced or metastatic disease requiring hormonal 
therapy, or androgen-insensitive disease.33 Green et al 
explored more historical literature from 1966 until 
2012.35 They included four studies which looked at life 
expectancy in men with localised PCa, two of which were 
included in our study.25 28 The other two were models 
from Albertsen et al in 1996 which was prior to our study 
dates, and from Walz et al in 2007 which focused exclu-
sively on non-cancer mortality and therefore did not 
meet our eligibility criteria.38 39 A recent review into deci-
sion-making tools again took an overview of tools avail-
able for use at different points in the patient pathway.40 
Here, the only mentioned models that predicted survival 
were all post-prostatectomy models.40 In 2015 Kent and 
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Vickers reported on ‘gross deficiencies’ in current tools 
for prediction of non-PCa death and concluded that they 
were unable to identify a suitable life expectancy tool.41 
These previous reviews all suggest there is a lack of focus 
on and availability of good quality survival models.
Interpretation of findings
Although a number of previous reviews have been 
published, ours represents the most systematic and 
contemporary work focused towards the decision 
dilemma that patients and clinicians face, as it includes 
only models that are available at the pretreatment stage 
and that are not treatment-specific. This review demon-
strates that only a small number of models for this setting 
have been published using long-term survival as an 
endpoint, and only three have been externally validated. 
However, the number of events reported in these three 
validation studies were well in excess of the 100 suggested 
as the minimum number needed for adequate valida-
tion.42 Within the external validations, model discrim-
ination of up to 0.81 was reported for disease related 
mortality.30 31 The included studies highlight the poten-
tial for using large datasets to develop prognostic models. 
These have the advantage of providing data from ‘real-
world’ settings, outside of the clinical trial context or data 
exclusively from specialised centres. Our included studies 
commonly used elements of good study design that would 
be in keeping with the AJCC acceptance criteria for risk 
models.13 For example, criteria that were seen in all 
studies, were that the prognostic time-zero was well-de-
fined, and that model developments have been published 
in well regarded peer-reviewed journals. However, 
other criteria were lacking such as reporting measures 
of discrimination, assessing calibration and thorough 
reporting of missing data in validation work.
The most robust tools we found are the three that have 
been externally validated – namely the Cambridge Prog-
nostic Groups, The SEER Cancer Survival Calculator and 
the UCSF CAPRA score. Of note, the Cambridge Prog-
nostic Group stratification criteria has not previously 
been summarised in prior reviews, as both its develop-
ment and validation have been published in the last few 
years.27 31 However, the SEER calculator has never been 
released for public use. Each of the other two models 
have significant shortcomings by disregarding treatment 
effect, focusing only on disease-specific mortality and 
ignoring comorbidity such that their value at the point 
of diagnosis is diminished. Importantly, each of the three 
external validation studies also had potential flaws in 
their design, using predominantly complete-case analyses 
and non-independent authors.30–32
Many of the included studies used historical cohorts. 
This is a necessity when using long-term survival as an 
outcome, but, raises issues of generalisability to men diag-
nosed in the contemporary setting. The uptake of prebi-
opsy multiparametric MRI and targeted biopsies, may for 
instance impact on the type of PCa detected and affect 
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Another issue was of small cohorts and low numbers of 
events in some cases, often as a result of relatively short 
follow-up. The value of 5 year outcomes themselves is ques-
tionable given randomised control trial data on survival 
in non-metastatic PCa would suggest cancer-survival over 
this timeframe is incredibly high.44 An important feature 
of any prognostic model should be its usability and appli-
cability to a man diagnosed today. However, with unquan-
tified missing data this applicability becomes less clear. 
Dealing with PCSM in isolation may also be problem-
atic, not least because of the importance of competing 
risks of death in a disease that affects older men.45 In 
this review we see that all but two included models were 
derived from North American data, such that generalis-
ability to European or UK men could be questioned, with 
differing approaches to PSA-testing and different health-
care contexts. This is particularly relevant with regards 
to screening, whereby historical American cohorts are 
likely to have been detected through PSA screening, such 
that issues of lead time bias and detection of cancers that 
would not be considered clinically-significant may affect 
model generalisability to modern practice.
Access for clinicians and patients to know about and 
use models should be easy with modern web-based soft-
ware. However, we found models were often only avail-
able in paper nomograms published with the article. 
Rather than online resources increasing the availability 
of models, there is the suggestion of the opposite occur-
ring, with sites such as www. nomogram. org and www. 
clin icri skca lcul ators. org which were previously cited in 
reviews no longer being available online.36 Indeed, the 
SEER Cancer Survival Calculator, one of the most prom-
ising models we explored, which was also externally vali-
dated, was never made available online or for clinical 
use.23 30 The UCSF CAPRA score ( www. urology. ucsf. edu) 
and Cambridge Prognostic Groups ( www. camb ridg epro 
gnos ticgroup. com) on the other hand are freely available 
online. Online publication does not in itself difficulty in 
accessing models, or a reluctance to fully share coeffi-
cients may partly explain the lack of external validations 
by researchers outside of the original models’ author-
ship group. Another hurdle to acceptance will be the 
‘face validity’ of a model. For example, in any PCa prog-
nostic model clinicians would likely expect grade, PSA 
and stage to be incorporated as a minimum set of vari-
ables; each of which has been shown to be independently 
prognostic.46–48 However, two of the models based on the 
largest dataset failed to include PSA which is inadequately 
recorded in the SEER database.23 30 A number of the 
other models used 3-strata grade classifications, rather 
than the full Gleason grade system, or the contemporary 
grade group system, which would again seem inadequate 
for a modern PCa model.49
A key step in the development of any prognostic 
model, following validation, should be a clinical impact 
study to quantify whether the model’s use improves deci-
sion-making and patient outcomes within a comparative 
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the scope of this formalised review, but no such studies 
were found on simple literature review. These studies 
not only assess whether use of the model is an improve-
ment on standard care, but also enable the study of 
factors that may affect implementation into care, such 
as the acceptability and ease of use to clinicians or 
patients, which can be difficult to assess in a review such 
as this.50 Impact studies can also help to bridge the gap 
between clinical validity and clinical utility, as utility of 
a model is not proportional to its prognostic capabili-
ties. This has recently been explored further in a review 
on the UCSF CAPRA score, which confirmed its prog-
nostic capacities, but was unable to demonstrate clin-
ical usefulness – particularly when deliberating between 
different treatment strategies.51
strengths and limitations at review level
While this review has particular strengths in its broad 
coverage of the literature and search strategy, we recog-
nise potential limitations. Although we have assessed 
bias within individual studies we recognise that risk of 
bias will also exist across studies, driven particularly by 
publication bias and selective reporting within studies 
which we were unable to assess. Other limitations to 
our review may relate to our timeframe of inclusion of 
studies only from 2000 onwards. Models developed prior 
to this time may have undergone more thorough testing 
or validation and clinical impact assessment. However, 
our rationale for focusing on this contemporary time 
period was to investigate models appropriate to modern 
management; with significant changes having taken 
place in patient management and diagnostic practice 
since that time.43 49
We recognise that exciting developments are also 
underway to propose genomical or biomarker-based 
prognostic indicators.52 Many of these are currently 
reported as single parameter studies, rather than being 
incorporated into existing models. As such these would 
not meet the eligibility criteria for this review. As others 
have suggested, any incremental value of these models 
should be assessed against ‘a gold-standard multivari-
able clinical prognostic model’.53
COnClusIOn
Very few long-term prognostic models exist to inform the 
predominant decision dilemma of whether to undergo 
treatment or not after first diagnosis of non-metastatic 
prostate cancer. Current models are limited by inadequate 
external validation and fall short of many of the expec-
tations of an unbiased, high-quality prognostic model.13 
The most robust available tools are the Cambridge Prog-
nostic Groups and the UCSF CAPRA score. However, 
both have significant shortcomings and are limited in 
their applicability at diagnosis by failing to include treat-
ment effect, and disregarding non-cancer mortality. Work 
should focus on developing prognostic models built on 
long-term survival outcomes which maximally utilise avail-
able clinico-pathological information and contextualise 
PCa within a patients context of competing risks. High 
quality models including treatment effect are overdue, 
and crucial if both undertreatment and overtreatment of 
prostate cancer is to be minimised.
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